Targeting the mTOR Signaling Pathway Utilizing Nanoparticles: A Critical Overview.

Abstract

Proteins of the mammalian target of rapamycin (mTOR) signaling axis are overexpressed or mutated in cancers. However, clinical inhibition of mTOR signaling as a therapeutic strategy in oncology shows rather limited progress. Nanoparticle-based mTOR targeted therapy proposes an attractive therapeutic option for various types of cancers. Along with the progress in the biomedical applications of nanoparticles, we start to realize the challenges and opportunities that lie ahead. Here, we critically analyze the current literature on the modulation of mTOR activity by nanoparticles, demonstrate the complexity of cellular responses to functionalized nanoparticles, and underline challenges lying in the identification of the molecular mechanisms of mTOR signaling affected by nanoparticles. We propose the idea that subcytotoxic doses of nanoparticles could be relevant for the induction of subcellular structural changes with possible involvement of mTORC1 signaling. The evaluation of the mechanisms and therapeutic effects of nanoparticle-based mTOR modulation will provide fundamental knowledge which could help in developing safe and efficient nano-therapeutics.

• Authors: Mariia Lunova, Barbora Smolková, Anna Lynnyk, Mariia Uzhytchak, Milan Jirsa, Šárka Kubinová, Alexandr Dejneka, Oleg Lunov
• Journal: Cancers (Cancers (Basel)) Vol. 11 Issue 1 (Jan 11 2019) ISSN: 2072-6694 [Print] Switzerland
• PMID: 30642006 (Publication Type: Journal Article, Review)